Table 1.
Patient baseline characteristics in relation to FCGR3A-V/F158 genotype.
| Characteristic | All Patients | F/F158 | V/F158 | V/V158 | P value |
|---|---|---|---|---|---|
| (n = 1,940) | (n = 799) | (n = 884) | (n = 257) | ||
| Female recipient sex, n (%) | 762 (39) | 292 (37) | 358 (40) | 110 (43) | 0.11 |
| Recipient age, mean ± SD (years) | 46.8 ± 13.7 | 46.8 ± 13.6 | 46.3 ± 13.8 | 48.9 ± 13.3 | 0.021 |
| Geographic origin, n (%) | 0.57 | ||||
| Europe | 1,729 (89) | 706 (88) | 795 (90) | 228 (89) | |
| Northern America | 211 (11) | 93 (12) | 89 (10) | 29 (11) | |
| First renal allograft, n (%) | 1,681 (87) | 704 (88) | 758 (86) | 219 (85) | 0.28 |
| Underlying renal disease, n (%) | 0.78 | ||||
| Glomerulonephritis | 626 (32) | 253 (32) | 282 (32) | 91 (35) | |
| Polycystic kidneys | 241 (12) | 94 (12) | 114 (13) | 34 (13) | |
| Diabetes mellitus | 174 (9) | 78 (10) | 74 (8) | 22 (9) | |
| Other | 899 (46) | 374 (47) | 414 (47) | 110 (43) | |
| Donor sex, n (%) | 0.50 | ||||
| Female | 768 (40) | 308 (39) | 350 (40) | 110 (43) | |
| Male | 1,169 (60) | 488 (61) | 534 (60) | 147 (57) | |
| Donor age, mean ± SD (years) | 40.4 ± 16.7 | 39.9 ± 16.7 | 40.7 ± 16.6 | 41.2 ± 16.8 | 0.58 |
| Cold ischemia time, mean ± SD (hours) | 20.3 ± 8.0 | 20.2 ± 7.8 | 20.3 ± 8.1 | 20.4 ± 8.5 | 0.78 |
| HLA A+B+DR mismatches, n (%) | 0.87 | ||||
| 0 – 1 | 227 (12) | 98 (12) | 103 (12) | 26 (10) | |
| 2 – 4 | 1,440 (74) | 585 (73) | 659 (75) | 196 (76) | |
| 5 – 6 | 273 (14) | 116 (15) | 122 (14) | 35 (14) | |
| Panel-reactive antibodies, n (%) | 0.23 | ||||
| = 0% | 1,370 (76) | 581 (78) | 608 (74) | 181 (75) | |
| > 0% | 438 (24) | 166 (22) | 213 (26) | 59 (25) | |
| Initial immunosuppression, n (%) | 0.55 | ||||
| Cyclosporine A | 1,540 (79) | 638 (80) | 707 (80) | 195 (76) | |
| Tacrolimus | 304 (16) | 126 (16) | 131 (15) | 47 (18) | |
| No calcineurin inhibitor | 96 (5) | 35 (4) | 46 (5) | 15 (6) | |
| Azathioprine | 903 (47) | 379 (47) | 417 (47) | 107 (42) | 0.44 |
| Mycophenolic acid | 648 (33) | 256 (32) | 299 (34) | 93 (36) | |
| No antimetabolite agent | 389 (20) | 164 (21) | 168 (19) | 57 (22) | |
| Induction therapy, n (%) | 0.45 | ||||
| IL-2R antibody | 161 (8) | 65 (9) | 69 (8) | 27 (11) | |
| Depleting anti-lymphocyte agent | 499 (26) | 164 (22) | 201 (24) | 54 (22) | |
| Without | 1,252 (65) | 533 (70) | 559 (67) | 160 (66) |
F, phenylalanine; V, valine; SD, standard deviation; HLA, human leukocyte antigen; IL-2R, interleukin 2 receptor.